Basic Information
Somac Control
Regulatory Information
EMEA/H/C/001098
Authorised
June 12, 2009
February 19, 2009
16
May 24, 2023
Company Information
Germany
Byk-Gulden-Strasse 2 D-78467 Konstanz
Takeda GmbH
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Somac Control. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Somac Control.